Aleks joined Novo A/S in September 2014 as Asset Director in Novo Large Investments taking part in managing and developing the growing portfolio of investments.. Prior to joining Novo, Aleks was employed as Vice President in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment. prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.).. Aleks holds a Ph.D. in Biochemical Engineering (1999) and a M.Sc. in Chemical Engineering Practice (1995) from Massachusetts Institute of Technology.. Aleks is a member of the board of directors of Symphogen A/S and Xellia Pharmaceuticals ApS.
